Optimization of ferric chloride induced thrombosis model in rats: Effect of anti-platelet and anti-coagulant drugs

Journal of Pharmacological and Toxicological Methods

Volumn 61, Issue 3, 2010, Pages 287-291

  Surin, W R ^a   Prakash, P ^a   Barthwal, M K ^a   Dikshit, M ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Aspirin; Clopidogrel; Ferric chloride; Heparin and warfarin; Thrombosis; Ticlopidine

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FERRIC CHLORIDE; HEPARIN; TICLOPIDINE; WARFARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAROTID ARTERY OBSTRUCTION; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; DISEASE MODEL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; MALE; NONHUMAN; PRIMARY PREVENTION; PROCESS OPTIMIZATION; RAT; REPEATED DRUG DOSE; SINGLE DRUG DOSE;

ANIMALS; ANTICOAGULANTS; CHLORIDES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FERRIC COMPOUNDS; MALE; PLATELET AGGREGATION INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; THROMBOSIS;

ANIMALIA; RATTUS;

EID: 77952288690     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2009.11.002     Document Type: Article

References (65)

1. Andre P., Bal dit Sollier C., Bonneau M., Pignaud G., Hainaud P., Azzam K., et al. Which experimental model to choose to study arterial thrombosis and evaluate potentially useful therapeutics?. Haemostasis 1996, 26(Suppl 4):55-69.
2. Angelillo-Scherrer A., de Frutos P., Aparicio C., Melis E., Savi P., Lupu F., et al. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nature Medicine 2001, 7(2):215-221.
3. Aoki T., Cox D., Senzaki K., Seki J., Tanaka A., Takasugi H., et al. Comparison of the antithrombotic effects of FK633, GPIIb/IIIa antagonist, and aspirin in a guinea pig thrombosis model. Thrombosis Research 1998, 89(3):129-136.
4. Bhatt D.L., Topol E.J. Scientific and therapeutic advances in antiplatelet therapy. Nature Reviews Drug Discovery 2003, 2(1):15-28.
5. Biller J., Bruno A., Adams H.P., Godersky J.C., Loftus C.M., Mitchell V.L., et al. A randomized trial of aspirin or heparin in hospitalized patients with recent transient ischemic attacks. A pilot study. Stroke 1989, 20(4):441-447.
6. Bird J.E., Giancarli M.R., Allegretto N., Barbera F., Wong P., Schumacher W.A., et al. Prediction of the therapeutic index of marketed anti-coagulants and anti-platelet agents by guinea pig models of thrombosis and hemostasis. Thrombosis Research 2008, 123(1):146-158.
7. Boos C.J., Lip G.Y. Blood clotting, inflammation, and thrombosis in cardiovascular events: perspectives. Frontiers Biosciences 2006, 11:328-336.
8. Broersma R.J., Kutcher L.W., Heminger E.F. The effect of thrombin inhibition in a rat arterial thrombosis model. Thrombosis Research 1991, 64(4):405-412.
9. Bugge T.H., Flick M.J., Daugherty C.C., Degen J.L. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes & Development 1995, 9(7):794-807.
10. Bugge T.H., Suh T.T., Flick M.J., Daugherty C.C., Romer J., Solberg H., et al. The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. The Journal of Biological Chemistry 1995, 270(28):16886-16894.
11. CAPRIE Steering Committee. (1996). A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 348(9038), 1329-1339.
12. Carmeliet P., Moons L., Stassen J.M., De Mol M.L., Bouche A., van den Oord J.J., et al. Vascular wound healing and neointima formation induced by perivascular electric injury in mice. The American Journal of Pathology 1997, 150(2):761-776.
13. Chakrabarti R., Das S.K. Advances in antithrombotic agents. Cardiovascular & Hematological Agents in Medicinal Chemistry 2007, 5(3):175-185.
14. Chou J., Mackman N., Merrill-Skoloff G., Pedersen B., Furie B.C., Furie B. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood 2004, 104(10):3190-3197.
15. Damiano B.P., Mitchell J.A., Giardino E., Corcoran T., Haertlein B.J., de Garavilla L., et al. Antiplatelet and antithrombotic activity of RWJ-53308, a novel orally active glycoprotein IIb/IIIa antagonist. Thrombosis Research 2001, 104(2):113-126.
16. Day S.M., Reeve J.L., Myers D.D., Fay W.P. Murine thrombosis models. Thrombosis and Haemostasis 2004, 92(3):486-494.
17. Daykin H.J., Sturgeon S.A., Jones C., Wright C.E. Arterial antithrombotic effects of aspirin, heparin, enoxaparin and clopidogrel alone, or in combination, in the rat. Thrombosis Research 2006, 118(6):755-762.
18. Denis C., Methia N., Frenette P.S., Rayburn H., Ullman-Cullere M., Hynes R.O., et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proceedings of the National Academy of Sciences of the United States of America 1998, 95(16):9524-9529.
19. Elg M., Gustafsson D., Carlsson S. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thrombosis Research 1999, 94(3):187-197.
20. Farrehi P.M., Ozaki C.K., Carmeliet P., Fay W.P. Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation 1998, 97(10):1002-1008.
21. Fay W.P., Parker A.C., Ansari M.N., Zheng X., Ginsburg D. Vitronectin inhibits the thrombotic response to arterial injury in mice. Blood 1999, 93(6):1825-1830.
22. Fruchtman S., Aledort L.M. Disseminated intravascular coagulation. Journal of the American College of Cardiology 1986, 8(6 Suppl B):159B-167B.
23. Furie B. Mutations in protein C: molecular pathology of thrombosis. The Journal of Laboratory and Clinical Medicine 1992, 119(6):592-593.
24. Fuster V., Ip J.H., Badimon L., Badimon J.J., Stein B., Chesebro J.H. Importance of experimental models for the development of clinical trials on thromboatherosclerosis. Circulation 1991, 83(6 Suppl):IV15-IV25.
25. Green D. Coagulation cascade. Hemodialysis International International Symposium on Home Hemodialysis 2006, 10(Suppl 2):S2-S4.
26. Gui T., Reheman A., Funkhouser W.K., Bellinger D.A., Hagaman J.R., Stafford D.W., et al. In vivo response to vascular injury in the absence of factor IX: examination in factor IX knockout mice. Thrombosis Research 2007, 121(2):225-234.
27. Hass W.K., Easton J.D., Adams H.P., Pryse-Phillips W., Molony B.A., Anderson S., et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. The New England Journal of Medicine 1989, 321(8):501-507.
28. Heckel J.L., Sandgren E.P., Degen J.L., Palmiter R.D., Brinster R.L. Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator. Cell 1990, 62(3):447-456.
29. Hirsh J. New anticoagulants. American Heart Journal 2001, 142(2 Suppl):S3-S8.
30. Horton J.D., Bushwick B.M. Warfarin therapy: evolving strategies in anticoagulation. American Family Physician 1999, 59(3):635-646.
31. Katori M. Thrombus models and mechanisms of action of anti-platelet drugs. Nippon Yakurigaku Zasshi 1992, 100(3):271-277.
32. Kurz K.D., Main B.W., Sandusky G.E. Rat model of arterial thrombosis induced by ferric chloride. Thrombosis Research 1990, 60(4):269-280.
33. Leadley R.J., Chi L., Rebello S.S., Gagnon A. Contribution of in vivo models of thrombosis to the discovery and development of novel antithrombotic agents. Journal of Pharmacological and Toxicological Methods 2000, 43(2):101-116.
34. Le Menn R., Bara L., Samama M. Ultrastructure of a model of thrombogenesis induced by mechanical injury. Journal of Submicroscopic Cytology 1981, 13(4):537-549.
35. Lockyer S., Kambayashi J. Demonstration of flow and platelet dependency in a ferric chloride-induced model of thrombosis. Journal of Cardiovascular Pharmacology 1999, 33(5):718-725.
36. Lockyer S., Okuyama K., Begum S., Le S., Sun B., Watanabe T., et al. GPVI-deficient mice lack collagen responses and are protected against experimentally induced pulmonary thromboembolism. Thrombosis Research 2006, 118(3):371-380.
37. Myers D.D., Hawley A.E., Farris D.M., Wrobleski S.K., Thanaporn P., Schaub R.G., et al. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. Journal of Vascular Surgery 2003, 38(5):1075-1089.
38. Nagai N., Hoylaerts M.F., Cleuren A.C., Van Vlijmen B.J., Lijnen H.R. Obesity promotes injury induced femoral artery thrombosis in mice. Thrombosis Research 2008, 122(4):549-555.
39. Pearson T.A., LaCava J., Weil H.F. Epidemiology of thrombotic-hemostatic factors and their associations with cardiovascular disease. The Americal Journal of Clinical Nutrition 1997, 65(5 Suppl):1674S-1682S.
40. Philp R.B. Experimental animal models of arterial thrombosis and the screening of platelet-inhibiting, anti-thrombotic drugs: a review. Methods and Findings in Experimental and Clinical Pharmacology 1979, 1(4):197-224.
41. Pilgeram L.O. Haemostatic factors and coronary heart disease. Biomedicine and Pharmacotherapy 1982, 36(4):187-189.
42. Reimann-Hunziker G. Uber experimentelle Thrombose und ihre Behandlung mit Heparin. Schweizerische Medizinische Wochenschrift 1944, 74:66-99.
43. Renne T., Pozgajova M., Gruner S., Schuh K., Pauer H.U., Burfeind P., et al. Defective thrombus formation in mice lacking coagulation factor XII. The Journal of Experimental Medicine 2005, 202(2):271-281.
44. Robinson M.A., Welsh D.C., Bickel D.J., Lynch J.J., Lyle E.A. Differential effects of sodium nitroprusside and hydralazine in a rat model of topical FeCl3-induced carotid artery thrombosis. Thrombosis Research 2003, 111(1-2):59-64.
45. Rosen E.D., Raymond S., Zollman A., Noria F., Sandoval-Cooper M., Shulman A., et al. Laser-induced noninvasive vascular injury models in mice generate platelet- and coagulation-dependent thrombi. The American Journal of Pathology 2001, 158(5):1613-1622.
46. Savi P., Bernat A., Dumas A., Ait-Chek L., Herbert J.M. Effect of aspirin and clopidogrel on platelet-dependent tissue factor expression in endothelial cells. Thrombosis Research 1994, 73(2):117-124.
47. Schumacher W.A., Heran C.L., Steinbacher T.E., Youssef S., Ogletree M.L. Superior activity of a thromboxane receptor antagonist as compared with aspirin in rat models of arterial and venous thrombosis. Journal of Cardiovascular Pharmacology 1993, 22(4):526-533.
48. Schumacher W.A., Steinbacher T.E., Heran C.L., Megill J.R., Durham S.K. Effects of antithrombotic drugs in a rat model of aspirin-insensitive arterial thrombosis. Thrombosis and Haemostasis 1993, 69(5):509-514.
49. Shebuski R.J., Bush L.R., Gagnon A., Chi L., Leadley R.J. Development and applications of animal models of thrombosis. Methods in Molecular Medicine 2004, 93:175-219.
50. Shimazawa M., Takiguchi Y., Umemura K., Kondo K., Nakashima M. Antithrombotic effects in a rat model of aspirin-insensitive arterial thrombosis of desethyl KBT-3022, the main active metabolite of a new antiplatelet agent, KBT-3022. European Journal of Pharmacology 1997, 328(2-3):183-189.
51. Smith G.F., Neubauer B.L., Sundboom J.L., Best K.L., Goode R.L., Tanzer L.R., et al. Correlation of the in vivo anticoagulant, antithrombotic, and antimetastatic efficacy of warfarin in the rat. Thrombosis Research 1988, 50(1):163-174.
52. Sugidachi A., Asai F., Ogawa T., Inoue T., Koike H. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. British Journal of Pharmacology 2000, 129(7):1439-1446.
53. Tanaka T., Sato R., Kurimoto T. Z-335, a new thromboxane A(2) receptor antagonist, prevents arterial thrombosis induced by ferric chloride in rats. European Journal of Pharmacology 2000, 401(3):413-418.
54. Tang Z., Wang Y., Xiao Y., Zhao M., Peng S. Anti-thrombotic activity of PDR, a newly synthesized L-Arg derivative, on three thrombosis models in rats. Thrombosis Research 2003, 110(2-3):127-133.
55. Tseng M.T., Dozier A., Haribabu B., Graham U.M. Transendothelial migration of ferric ion in FeCl3 injured murine common carotid artery. Thrombosis Research 2006, 118(2):275-280.
56. van den Eijnden M.M., Steenhauer S.I., Reitsma P.H., Bertina R.M. Tissue factor expression during monocyte-macrophage differentiation. Thrombosis and Haemostasis 1997, 77(6):1129-1136.
57. van Giezen J.J., Wahlund G. Nerme, Abrahamsson T. The Fab-fragment of a PAI-1 inhibiting antibody reduces thrombus size and restores blood flow in a rat model of arterial thrombosis. Thrombosis and Haemostasis 1997, 77(5):964-969.
58. Verbeuren T.J. Experimental models of thrombosis and atherosclerosis. Therapie 2006, 61(5):379-387.
59. Wang X., Cheng Q., Xu L., Feuerstein G.Z., Hsu M.Y., Smith P.L., et al. Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. Journal of Thrombosis and Haemostasis 2005, 3(4):695-702.
60. Wang X., Xu L. An optimized murine model of ferric chloride-induced arterial thrombosis for thrombosis research. Thrombosis Research 2005, 115(1-2):95-100.
61. Watson B.D., Dietrich W.D., Busto R., Wachtel M.S., Ginsberg M.D. Induction of reproducible brain infarction by photochemically initiated thrombosis. Annals of Neurology 1985, 17(5):497-504.
62. Wessler S., Gitel S.N. Pharmacology of heparin and warfarin. Journal of the American College of Cardiology 1986, 8(6 Suppl B):10B-20B.
63. Wessler S., Reimer S.M., Sheps M.C. Biologic assay of a thrombosis-inducing activity in human serum. Journal of Applied Physiology 1959, 14:943-946.
64. Westrick R.J., Winn M.E., Eitzman D.T. Murine models of vascular thrombosis (Eitzman series). Arteriosclerosis, Thrombosis, and Vascular Biology 2007, 27(10):2079-2093.
65. Zheng X., Saunders T.L., Camper S.A., Samuelson L.C., Ginsburg D. Vitronectin is not essential for normal mammalian development and fertility. Proceedings of the National Academy of Sciences of the United States of America 1995, 92(26):12426-12430.